Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

Blood

Volumn 127, Issue 22, 2016, Pages 2672-2681

  Emile, Jean François ^a,b   Abla, Oussama ^c   Fraitag, Sylvie ^d   Horne, Annacarin ^e   Haroche, Julien ^f,g   Donadieu, Jean ^a,h   Requena Caballero, Luis ⁱ   Jordan, Michael B ^j   Abdel Wahab, Omar ^k   Allen, Carl E ^l   Charlotte, Frédéric ^f,g   Diamond, Eli L ^k   Egeler, R Maarten ^c   Fischer, Alain ^d,m   Herrera, Juana Gil ⁿ   Henter, Jan Inge ^e   Janku, Filip ^o   Merad, Miriam ^p   Picarsic, Jennifer ^q   Rodriguez Galindo, Carlos ^r   Rollins, Barret J ^r,s   Tazi, Abdellatif ^t   Vassallo, Robert ^u   Weiss, Lawrence M ^v   Histiocyte Society, ^w   more..

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d HÔPITAL NECKER ENFANTS MALADES   (France)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g SORBONNE UNIVERSITÉ   (France)

^h ARMAND TROUSSEAU HOSPITAL   (France)

ⁱ UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^j UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l TEXAS CHILDREN S CANCER CENTER   (United States)

^m IMAGINE INSTITUTE   (France)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^p MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^q CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^r DANA FARBER CANCER INSTITUTE   (United States)

^s HARVARD MEDICAL SCHOOL   (United States)

^t SAINT LOUIS HOSPITAL   (France)

^u Mayo Clinic College of Medicine   (United States)

^v Clarient Pathology Services Inc   (United States)

^w Saint Louis Hospital ^*

more..

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G4;

CLINICAL FEATURE; CUTANEOUS HISTIOCYTOSIS; DENDRITIC CELL; DISEASE CLASSIFICATION; ERDHEIM CHESTER DISEASE; GENE TRANSLOCATION; HEMOPHAGOCYTIC SYNDROME; HISTIOCYTE; HISTIOCYTOSIS; HISTOLOGY; HUMAN; LANGERHANS CELL HISTIOCYTOSIS; MACROPHAGE; MACROPHAGE ACTIVATION SYNDROME; MALIGNANT HISTIOCYTOSIS; MOLECULAR PATHOLOGY; MONONUCLEAR PHAGOCYTE; MUCOCUTANEOUS HISTIOCYTOSIS; PATHOGENESIS; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; SECOND CANCER; SINUS HISTIOCYTOSIS; SOMATIC MUTATION; XANTHOGRANULOMA; ADULT; CLASSIFICATION; FEMALE; HISTIOCYTIC LYMPHOMA; MALE; PATHOLOGY;

ADULT; DENDRITIC CELLS; FEMALE; HISTIOCYTIC DISORDERS, MALIGNANT; HISTIOCYTOSIS, LANGERHANS-CELL; HISTIOCYTOSIS, NON-LANGERHANS-CELL; HUMANS; MACROPHAGES; MALE;

EID: 84971328245     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-01-690636     Document Type: Review

References (95)

1. Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Lancet. 1987;1(8526):208-209.
2. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology. 2013;140(1):22-30.
3. Guilliams M, Ginhoux F, Jakubzick C, et al. Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny. Nat Rev Immunol. 2014;14(8):571-578.
4. Hervier B, Haroche J, Arnaud L, et al; French Histiocytoses Study Group. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood. 2014;124(7):1119-1126.
5. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
6. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120(13):2700-2703.
7. Emile JF, Diamond EL, Hélias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014;124(19):3016-3019.
8. Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6(2):154-165.
9. Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004. Pediatr Blood Cancer. 2008;51(1):71-75.
10. Stålemark H, Laurencikas E, Karis J, Gavhed D, Fadeel B, Henter JI. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer. 2008;51(1):76-81.
11. Aricò M, Haupt R, Russotto VS, Bossi G, Scappaticci S, Danesino C. Langerhans cell histiocytosis in two generations: a new family and review of the literature. Med Pediatr Oncol. 2001;36(2):314-316.
12. Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. 2002;346(7):484-490.
13. Laurencikas E, Gavhed D, Stålemark H, et al. Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: a population based study. Pediatr Blood Cancer. 2011;56(2):250-257.
14. Emile JF, Wechsler J, Brousse N, et al. Langerhans' cell histiocytosis. Definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg Pathol. 1995;19(6):636-641.
15. Haupt R, Minkov M, Astigarraga I, et al; Euro Histio Network. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013;60(2):175-184.
16. O'Malley DP, Agrawal R, Grimm KE, et al. Evidence of BRAF V600E in indeterminate cell tumor and interdigitating dendritic cell sarcoma. Ann Diagn Pathol. 2015;19(3):113-116.
17. Brown RA, Kwong BY, McCalmont TH, et al. ETV3-NCOA2 in indeterminate cell histiocytosis: clonal translocation supports sui generis. Blood. 2015;126(20):2344-2345.
18. Chikwava K, Jaffe R. Langerin (CD207) staining in normal pediatric tissues, reactive lymph nodes, and childhood histiocytic disorders. Pediatr Dev Pathol. 2004;7(6):607-614.
19. Picarsic J, Jaffe R. Nosology and Pathology of Langerhans Cell Histiocytosis. Hematol Oncol Clin North Am. 2015;29(5):799-823.
20. Cohen-Barak E, Rozenman D, Schafer J, et al. An unusual co-occurrence of Langerhans cell histiocytosis and Rosai-Dorfman disease: report of a case and review of the literature. Int J Dermatol. 2014;53(5):558-563.
21. Feuillet S, Louis L, Bergeron A, et al. Pulmonary Langerhans cell histiocytosis associated with Hodgkin's lymphoma. Eur Respir Rev. 2010;19(115):86-88.
22. Magni M, Di Nicola M, Carlo-Stella C, et al. Identical rearrangement of immunoglobulin heavy chain gene in neoplastic Langerhans cells and B-lymphocytes: evidence for a common precursor. Leuk Res. 2002;26(12):1131-1133.
23. Donadieu J, Piguet C, Bernard F, et al. A new clinical score for disease activity in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2004;43(7):770-776.
24. Nanduri VR, Pritchard J, Levitt G, Glaser AW. Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis. Eur J Cancer. 2006;42(15):2563-2569.
25. Bernstrand C, Sandstedt B, Ahström L, Henter JI. Long-term follow-up of Langerhans cell histiocytosis: 39 years' experience at a single centre. Acta Paediatr. 2005;94(8):1073-1084.
26. Globerman H, Burstein S, Girardina PJ, Winchester P, Frankel S. A xanthogranulomatous histiocytosis in a child presenting with short stature. Am J Pediatr Hematol Oncol. 1991;13(1):42-46.
27. Diamond EL, Dagna L, Hyman DM, et al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124(4):483-492.
28. Haroche J, Amoura Z, Dion E, et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore). 2004;83(6):371-392.
29. Arnaud L, Malek Z, Archambaud F, et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum. 2009;60(10):3128-3138.
30. Haroche J, Cluzel P, Toledano D, et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation. 2009;119(25):e597-e598.
31. Arnaud L, Hervier B, Néel A, et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117(10):2778-2782.
32. Chan JK, Lamant L, Algar E, et al. ALK+ histiocytosis: a novel type of systemic histiocytic proliferative disorder of early infancy. Blood. 2008;112(7):2965-2968.
33. Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease [published correction appears in PLoS One. 2012;7(6)]. PLoS One. 2012;7(4):e33891.
34. Berres ML, Lim KP, Peters T, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups [published correction appears in J Exp Med. 2015;212(2):281]. J Exp Med. 2014;211(4):669-683.
35. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120(12):e28-e34.
36. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
37. Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014;124(19):3007-3015.
38. Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655-1658.
39. Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20):3152-3155.
40. Nelson DS, van Halteren A, Quispel WT, et al. MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. Genes Chromosomes Cancer. 2015;54(6):361-368.
41. Héritier S, Saffroy R, Radosevic-Robin N, et al. Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. Blood. 2015;125(15):2448-2449.
42. Diamond EL, Abdel-Wahab O, Pentsova E, et al. Detectionof an NRAS mutationin Erdheim-Chester disease. Blood. 2013;122(6):1089-1091.
43. Go H, Jeon YK, Huh J, et al. Frequent detection of BRAF(V600E) mutations in histiocytic and dendritic cell neoplasms. Histopathology. 2014;65(2):261-272.
44. Michonneau D, Kaltenbach S, Derrieux C, et al. BRAF(V600E) mutation in a histiocytic sarcoma arising from hairy cell leukemia. J Clin Oncol. 2014;32(35):e117-e121.
45. Idbaih A, Mokhtari K, Emile JF, et al. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology. 2014;83(16):1478-1480.
46. Kobayashi M, Tojo A. The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis. Blood. 2014;124(16):2610-2611.
47. Hyman DM, Diamond EL, Vibat CR, et al. Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2015;5(1):64-71.
48. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121(9):1495-1500.
49. Haroche J, Cohen-Aubart F, Emile JF, et al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF (V600E)-mutated Erdheim-Chester disease. J Clin Oncol. 2015;33(5):411-418.
50. Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726-736.
51. Héritier S, Jehanne M, Leverger G, et al. Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis. JAMA Oncol. 2015;1(6):836-838.
52. Zelger BWH, Cerio R. Xanthogranuloma is the archetype of non-Langerhans cell histiocytoses. Br J Dermatol. 2001;145(2):369-371.
53. Zelger B, Burgdorf WH. The cutaneous "histiocytoses". Adv Dermatol. 2001;17:77-114.
54. Weitzman S, Jaffe R. Uncommon histiocytic disorders: the non-Langerhans cell histiocytoses. Pediatr Blood Cancer. 2005;45(3):256-264.
55. Stinco G, Patriarca M, Di Loreto C, Patrone P. A histiocytic disorder that does not easily fit into the classification of the juvenile xanthogranuloma family. Int J Dermatol. 2013;52(7):849-855.
56. Vadoud-Seyedi J, Vadoud-Seyedi R, De Dobbeleer G. Progressive nodular histiocytomas. Br J Dermatol. 2000;143(3):678-679.
57. Dehner LP. Juvenile xanthogranulomas in the first two decades of life: a clinicopathologic study of 174 cases with cutaneous and extracutaneous manifestations. Am J Surg Pathol. 2003;27(5):579-593.
58. Verma SB. Generalized eruptive histiocytomas and juvenile eruptive xanthogranulomas in a 10-year-old boy: a potpourri of exotic terms indicating the need for unification. Int J Dermatol. 2012;51(4):445-447.
59. Trotta F, Colina M. Multicentric reticulohistiocytosis and fibroblastic rheumatism. Best Pract Res Clin Rheumatol. 2012;26(4):543-557.
60. Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41(1):1-29.
61. Johnson RL, Boisot S, Ball ED, Wang HY. A case of interdigitating dendritic cell sarcoma/histiocytic sarcoma-a diagnostic pitfall. Int J Clin Exp Pathol. 2014;7(1):378-385.
62. O'Malley DP, Zuckerberg L, Smith LB, et al. The genetics of interdigitating dendritic cell sarcoma share some changes with Langerhans cell histiocytosis in select cases. Ann Diagn Pathol. 2014;18(1):18-20.
63. Feldman AL, Arber DA, Pittaluga S, et al. Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone. Blood. 2008;111(12):5433-5439.
64. Shao H, Xi L, Raffeld M, et al. Clonally related histiocytic/dendritic cell sarcoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a study of seven cases. Mod Pathol. 2011;24(11):1421-1432.
65. Chen W, Jaffe R, Zhang L, et al. Langerhans cell sarcoma arising from chronic lymphocytic lymphoma/small lymphocytic leukemia: lineage analysis and BRAF V600E mutation study. N Am J Med Sci. 2013;5(6):386-391.
66. Castro EC, Blazquez C, Boyd J, et al. Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature. Pediatr Dev Pathol. 2010;13(3):225-237.
67. Mori M, Matsushita A, Takiuchi Y, et al. Histiocytic sarcoma and underlying chronic myelomonocytic leukemia: a proposal for the developmental classification of histiocytic sarcoma. Int J Hematol. 2010;92(1):168-173.
68. Edelbroek JR, Vermeer MH, Jansen PM, et al. Langerhans cell histiocytosis first presenting in the skin in adults: frequent association with a second haematological malignancy. Br J Dermatol. 2012;167(6):1287-1294.
69. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969;87(1):63-70.
70. Destombes P, Destombes M, Martin L. Pseudotumoral lymph node lipidic histiocytosis. Further case in a young Martinique woman [in French]. Bull Soc Pathol Exot. 1972;65(3):481-488.
71. Vaiselbuh SR, Bryceson YT, Allen CE, Whitlock JA, Abla O. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014;61(7):1329-1335.
72. Demicco EG, Rosenberg AE, Björnsson J, Rybak LD, Unni KK, Nielsen GP. Primary Rosai-Dorfman disease of bone: a clinicopathologic study of 15 cases. Am J Surg Pathol. 2010;34(9):1324-1333.
73. Andriko JA, Morrison A, Colegial CH, Davis BJ, Jones RV. Rosai-Dorfman disease isolated to the central nervous system: a report of 11 cases. Mod Pathol. 2001;14(3):172-178.
74. Tauziede-Espariat A, Polivka M, Chabriat H, Bouazza S, Sene D, Adle-Biassette H. A case report of meningeal Rosai-Dorfman disease associated with IgG4-related disease. Clin Neuropathol. 2015;34(6):343-349.
75. Vuong V, Moulonguet I, Cordoliani F, et al. Cutaneous revelation of Rosai-Dorfman disease: 7 cases [in French]. Ann Dermatol Venereol. 2013;140(2):83-90.
76. Menon MP, Evbuomwan MO, Rosai J, Jaffe ES, Pittaluga S. A subset of Rosai-Dorfman disease cases show increased IgG4-positive plasma cells: another red herring or a true association with IgG4-related disease? Histopathology. 2014;64(3):455-459.
77. Grabczynska SA, Toh CT, Francis N, Costello C, Bunker CB. Rosai-Dorfman disease complicated by autoimmune haemolytic anaemia: case report and review of a multisystem disease with cutaneous infiltrates. Br J Dermatol. 2001;145(2):323-326.
78. Molho-Pessach V, Ramot Y, Camille F, et al. H syndrome: the first 79 patients. J Am Acad Dermatol. 2014;70(1):80-88.
79. Bolze A, Abhyankar A, Grant AV, et al. A mild form of SLC29A3 disorder: a frameshift deletion leads to the paradoxical translation of an otherwise noncoding mRNA splice variant. PLoS One. 2012;7(1):e29708.
80. Maric I, Pittaluga S, Dale JK, et al. Histologic features of sinus histiocytosis with massive lymphadenopathy in patients with autoimmune lymphoproliferative syndrome. Am J Surg Pathol. 2005;29(7):903-911.
81. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis. Annu Rev Med. 2012;63:233-246.
82. Henter JI, Elinder G, Söder O, Hansson M, Andersson B, Andersson U. Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood. 1991;78(11):2918-2922.
83. Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
84. Fischer A, Cerf-Bensussan N, Blanche S, et al. Allogeneic bone marrow transplantation for erythrophagocytic lymphohistiocytosis. J Pediatr. 1986;108(2):267-270.
85. Trottestam H, Horne A, Aricò M, et al; Histiocyte Society. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577-4584.
86. Pachlopnik Schmid J, Côte M, Ménager MM, et al. Inherited defects in lymphocyte cytotoxic activity [published correction appears in Immunol Rev. 2010;236(1):276]. Immunol Rev. 2010;235(1):10-23.
87. Canna SW, de Jesus AA, Gouni S, et al. An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nat Genet. 2014;46(10):1140-1146.
88. Romberg N, Al Moussawi K, Nelson-Williams C, et al. Mutation of NLRC4 causes a syndrome of enterocolitis and autoinflammation. Nat Genet. 2014;46(10):1135-1139.
89. Cetica V, Sieni E, Pende D, et al. Genetic predisposition to hemophagocytic lymphohistiocytosis: Report on 500 patients from the Italian registry. J Allergy Clin Immunol. 2016;137(1):188-196.e4.
90. Zhang K, Jordan MB, Marsh RA, et al. Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH. Blood. 2011;118(22):5794-5798.
91. Bode SF, Ammann S, Al-Herz W, et al; Inborn Errors Working Party of the EBMT. The syndrome of hemophagocytic lymphohistiocytosis in primary immunodeficiencies: implications for differential diagnosis and pathogenesis. Haematologica. 2015;100(7):978-988.
92. Ramos-Casals M, Brito-Zerón P, López-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014;383(9927):1503-1516.
93. Imashuku S. Treatment of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis (EBV-HLH); update 2010. J Pediatr Hematol Oncol. 2011;33(1):35-39.
94. Athreya BH. Is macrophage activation syndrome a new entity? Clin Exp Rheumatol. 2002;20(2):121-123.
95. Ramanan AV, Baildam EM. Macrophage activation syndrome is hemophagocytic lymphohistiocytosis-need for the right terminology. J Rheumatol. 2002;29(5):1105.